Company news

CStone Pharmaceuticals news in 2025

CStone Pharmaceuticals's news releases, calls and decks from 2025, newest first.

View company

ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut

November 6, 2025

ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

October 19, 2025

CStone Announces 2025 Interim Results, Pipeline Acceleration and Value Potential Unlocked

August 15, 2025

CStone Signs Exclusive License Agreement with Istituto Gentili for Sugemalimab in Western Europe and the UK

July 8, 2025

CStone Announces Clinical Progress Update on CS2009

July 7, 2025

CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR

May 5, 2025

CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR

May 4, 2025

CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

March 27, 2025

CStone to Showcase Five Latest Research Achievements at AACR 2025

March 25, 2025

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

March 23, 2025

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

March 5, 2025

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

March 3, 2025

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab in JAMA

February 26, 2025

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

February 24, 2025

CStone Announces Inclusion of Cejemly as a First-Line Combination Therapy for NSCLC in ESMO Guideline

February 10, 2025

Decks in 2025